Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
  • Video
  • Noteworthy Articles
Immunexpress.com

Immunexpress Receives Early Stage Commercialisation Support to Further Develop SeptiCyte® PLUS

Immunexpress receives Early Stage Commercialisation support to further develop SeptiCyte®PLUS — designed to diagnose sepsis accurately within a clinically relevant timeframe. BRISBANE, Australia (February 18, 2014) – Today, Immunexpress Group (Immunexpress) announced it has received Early Stage Commercialisation support through Commercialisation Australia, an initiative of the Australian Government. The AUD...
Immunexpress.com

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection April 1, 2013 – Today, Immunexpress Group announced the granting of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment” in the European Union (EU). This patent...
Immunexpress.com

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients The MARS Consortium is one of the largest collaborations of academic and industry partners dedicated solely to improving sepsis outcomes SEATTLE, United States / EINDHOVEN, The Netherlands (April 10, 2013) –Today, the Immunexpress Group announced its collaboration...
Immunexpress.com

Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection

Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection SEATTLE, United States (November 21, 2012) – Today, Immunexpress Group announced the granting in the United States (U.S.) of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment.”...
Critical Care

Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis

Sutherland et al., Critical Care | A novel molecular biomarker test based on a panel of 42-gene expression markers has demonstrated a clinically relevant sensitivity and specificity profile, and has the capacity for early detection of sepsis via the monitoring of critical care patients.

If you are a member of the media, please contact:

Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com